Our Experience

New Chemical Entities, Formulations, and Drug Delivery Systems

Representative engagements have addressed:

• Aerosol-based microelectronic pulmonary drug delivery system for macromolecules
• Aerosol-based pulmonary drug delivery system for anticancer chemotherapeutics
• Aldose reductase-inhibiting small molecule for the indication of diabetic peripheral neuropathy
• Ammonium-linked phosphate-binding polymer powder for the management of hyperphosphatemia in chronic renal insufficiency and end-stage renal disease patients
• Anti-metabolite formulation for the indications of Crohn’s disease and ulcerative colitis
• Azulfidine-based formulation for the indication of inflammatory bowel disease maintenance therapy
• BCNU-delivering polyanhydride polymer drug delivery system for the indication of malignant glioma
• Bradykinin-based drug delivery system for neuropeptides
• Broad-spectrum nucleoside analog for the indications of non-small cell lung, breast, and ovarian cancer
• Calcium-mimetic PTH-modulating small molecule for the indications of primary and secondary hyperparathyroidism
• Carrier-based oral drug delivery system for lipopeptides and macromolecules
• Complement ligand-inhibiting immunomodulatory small molecule therapy for the indications of rheumatoid arthritis and Sjogren’s syndrome
• Corticosteroid-based immunomodulator for the indications of Crohn’s diseases and ulcerative colitis
• Corticotropin releasing hormone-antagonizing for the indication of stable angina
• Corticotropin releasing hormone-antagonizing small molecule for the indication of atopic dermatitis
• Cyclooxygenase-inhibiting small molecule for the indication of acute pain
• DHA-based fatty acid drug delivery system for neuropeptides
• Dry powder pulmonary drug delivery system for recombinant insulin
• Glucopolymer-based transperitoneal drug delivery system for anticancer chemotherapeutics
• Heat-activated liposomal drug delivery system for small molecules and biopharmaceuticals
• Histamine-agonizing small molecule for the indication of abortive migraine therapy
• Histamine-agonizing small molecule for the indication of irritable bowel syndrome
• Hormone-based metabolic control small molecule for the indication of adult Type II diabetes
• Integrin-inhibiting small molecule for the indication of inflammatory bowel disease
• Iontophoresis-based drug delivery system for ophthalamic small molecules
• Isomeric antimuscarinic small molecule for the indication of urge urinary incontinence
• Leukocyte migration-inhibiting small molecule for the indication of asthma
• Lipophilic morphine-based drug delivery system for neuropeptides
• Lipophilic transdermal drug delivery system for vasoactive small molecules
• Mesalamine-based local drug delivery formulation for the indication of acutely flaring inflammatory bowel disease
• Microparticulate-based high-dose oral drug delivery system for small molecules
• Microparticulate-based pulmonary drug delivery system for antiasthma steroids
• Nanoparticulate pulmonary drug delivery system for hydrophilic small molecules and proteins
• Nanoparticulate pulmonary reformulation system for HFA-based metered dose inhaler delivery of small molecules
• Neuroprotecting small molecule for the indications of ischemic and hemorrhagic stroke
• Neurotensin-antagonizing small molecule for the treatment of stable angina
• Nitric oxide modulating agent for the indications of paresthesia and peripheral neuropathy
• Nociceptin-antagonizing small molecule for the indication of acute and chronic pain
• Perfluorocarbon-based liquid for the indications of adult and infant respiratory distress syndrome
• Perfusion-based loaded cartridge drug delivery system for use during extended cardiopulmonary bypass procedures
• Permeability-enhancing oral drug delivery system for high-dose BCS Class III small molecules and lipoproteins
• Polyene antifungal pulmonary reformulation for the indication of pulmonary aspergillosis.
• Poly-lactide-glycolide-based injectable sustained-release drug delivery system for proteins and macromolecules
• Poly-lactide-glycolide-based injectable sustained-release drug delivery system for small molecule and peptide reformulation.
• Resperidone-based sustained release injectable formulation for the indication of schizophrenia
• Serotonin-antagonizing small molecule for the indication of preventive migraine therapy
• Transdermal patch drug delivery system for anti-inflammatory small molecules
• Transporter ligand-targeting oral drug delivery systems for macromolecules and peptides
• Vitamin D analog for the indication of ESRD-associated renal osteodystrophy